ProCE Banner Activity

Improving Outcomes in HER2-Negative Early Breast Cancer With Individualized Targeted Approaches

Clinical Thought

Expert highlights of how recent FDA approvals are expanding individualized treatment options with improved outcomes for HER2-negative early breast cancer.

Released: June 21, 2023

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Novartis, Puma; researcher (paid to institution): Genentech, Gilead, Lilly, Merck, Phillips.